Allela Omer Qutaiba B, Ali Noor Adel Mohammed, Sanghvi Gaurav, Roopashree R, Kashyap Aditya, Krithiga T, Panigrahi Rajashree, Kubaev Aziz, Kareem Radhwan Abdul, Sameer Hayder Naji, Yaseen Ahmed, Athab Zainab H, Adil Mohaned
College of Pharmacy, Alnoor University, Nineveh, Iraq.
Al-Amal College for Specialized Medical Science, Karbala, Iraq.
Stem Cell Rev Rep. 2025 Apr 8. doi: 10.1007/s12015-025-10873-0.
Viruses may cause a wide range of renal problems. Furthermore, many kidney diseases may be brought on by viral infections. Both the primary cause and a contributing factor of acute kidney injury (AKI) may be viral infections. As an example, it is recommended that patients with dengue virus (DENV) infections undergo careful monitoring of their AKI levels. Also, researchers' data so far lend credence to the several hypothesized pathophysiological mechanisms via which AKI can develop in SARS-CoV- 2 infection. Thus, it is critical to comprehend how viral infections cause AKI. Finding an effective method of treating AKI caused by viruses is also vital. Thus, a potential cell-free method for treating AKI that uses regenerative and anti-inflammatory processes is mesenchymal stem cells (MSCs) and their exosomes (MSC-EXOs). MSCs alleviate tissue damage and enhance protective effects on damaged kidneys in AKI. Furthermore, MSC-EXOs have exhibited substantial regulatory impact on a range of immune cells and exhibit robust immune regulation in the therapy of AKI. Thus, in models of AKI caused by ischemia-reperfusion damage, nephrotoxins, or sepsis, MSCs and MSC-EXOs improved renal function, decreased inflammation, and improved healing. Therefore, MSCs and MSC-EXOs may help treat AKI caused by different viruses. Consequently, we have explored several innovative and significant processes in this work that pertain to the role of viruses in AKI and the significance of viral illness in the onset of AKI. After that, we assessed the key aspects of MSCs and MSC-EXOs for AKI therapy. We have concluded by outlining the current state of and plans for future research into MSC- and EXO-based therapeutic approaches for the treatment of AKI brought on by viruses.
病毒可能引发多种肾脏问题。此外,许多肾脏疾病可能由病毒感染所致。病毒感染既可能是急性肾损伤(AKI)的主要病因,也可能是一个促成因素。例如,建议登革热病毒(DENV)感染患者仔细监测其AKI水平。此外,研究人员目前的数据证实了几种关于严重急性呼吸综合征冠状病毒2(SARS-CoV-2)感染时AKI可能的发病病理生理机制的假设。因此,理解病毒感染如何导致AKI至关重要。找到一种治疗由病毒引起的AKI的有效方法也至关重要。因此,一种潜在的利用再生和抗炎过程治疗AKI的无细胞方法是间充质干细胞(MSCs)及其外泌体(MSC-EXOs)。间充质干细胞可减轻组织损伤,并增强对AKI中受损肾脏的保护作用。此外,MSC-EXOs已对一系列免疫细胞表现出显著的调节作用,并在AKI治疗中展现出强大的免疫调节能力。因此,在由缺血再灌注损伤、肾毒素或败血症引起的AKI模型中,间充质干细胞和MSC-EXOs改善了肾功能,减轻了炎症,并促进了愈合。所以,间充质干细胞和MSC-EXOs可能有助于治疗由不同病毒引起的AKI。因此,在这项工作中,我们探索了几个与病毒在AKI中的作用以及病毒感染在AKI发病中的重要性相关的创新且重要的过程。之后,我们评估了间充质干细胞和MSC-EXOs用于AKI治疗的关键方面。我们通过概述基于间充质干细胞和外泌体的治疗方法在治疗由病毒引起的AKI方面的研究现状和未来计划得出结论。